Literature DB >> 17270305

Applications of carrier erythrocytes in delivery of biopharmaceuticals.

Mehrdad Hamidi1, Adbolhossein Zarrin, Mahshid Foroozesh, Soliman Mohammadi-Samani.   

Abstract

Carrier erythrocytes, resealed erythrocytes loaded by a drug or other therapeutic agents, have been exploited extensively in recent years for both temporally and spatially controlled delivery of a wide variety of drugs and other bioactive agents owing to their remarkable degree of biocompatibility, biodegradability and a series of other potential advantages. Biopharmaceuticals, therapeutically significant peptides and proteins, nucleic acid-based biologicals, antigens and vaccines, are among the recently focused pharmaceuticals for being delivered using carrier erythrocytes. In this article, the potential applications of erythrocytes in drug delivery have been reviewed with a particular stress on the studies and laboratory experiences on successful erythrocyte loading and characterization of the different classes of biopharmaceuticals.

Mesh:

Substances:

Year:  2006        PMID: 17270305     DOI: 10.1016/j.jconrel.2006.06.032

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  34 in total

1.  Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel.

Authors:  Gamaleldin I Harisa; Mohamed F Ibrahim; Fars Alanazi; Gamal A Shazly
Journal:  Saudi Pharm J       Date:  2013-01-07       Impact factor: 4.330

Review 2.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

Review 3.  Bio-inspired, bioengineered and biomimetic drug delivery carriers.

Authors:  Jin-Wook Yoo; Darrell J Irvine; Dennis E Discher; Samir Mitragotri
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

Review 4.  Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Int J Hematol Oncol       Date:  2016-05-05

5.  Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.

Authors:  Jorge F Coelho; Paula C Ferreira; Patricia Alves; Rosemeyre Cordeiro; Ana C Fonseca; Joana R Góis; Maria H Gil
Journal:  EPMA J       Date:  2010-04-10       Impact factor: 6.543

Review 6.  Erythrocyte-mediated delivery of recombinant enzymes.

Authors:  Vincenzo Leuzzi; Luigia Rossi; Claudia Gabucci; Francesca Nardecchia; Mauro Magnani
Journal:  J Inherit Metab Dis       Date:  2016-03-30       Impact factor: 4.982

Review 7.  Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.

Authors:  Carlos H Villa; Douglas B Cines; Don L Siegel; Vladimir Muzykantov
Journal:  Transfus Med Rev       Date:  2016-08-17

8.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.

Authors:  Juan-Carlos Murciano; Abd Al-Roof Higazi; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2009-07-16       Impact factor: 9.776

9.  L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).

Authors:  Young Min Kwon; Hee Sun Chung; Cheol Moon; James Yockman; Yoon Jeong Park; Scott D Gitlin; Allan E David; Victor C Yang
Journal:  J Control Release       Date:  2009-07-03       Impact factor: 9.776

Review 10.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.